The U.S. Food and Drug Administration (FDA) approved Myqorzo (aficamten) tablets to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
Similar Posts
Mark J. Savant, M.D – 712306 – 06/26/2025
Clinical InvestigatorAsahi Kasei Finechem Co., Ltd. – 11/14/2025
Asahi Kasei Finechem Co., Ltd. – 11/14/2025. Country: Japan. Record Type: 483Recall Alert: Baxter Permanently Removes Life2000 Ventilation System
Baxter is permanently removing all Life2000 Ventilation Systems after discovering a cybersecurity issue that may allow unauthorized access to the deviceCharles H. Harper, M.D. Norfolk, NE. EIR issued 11/13/2020
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 11/13/2020
Short Title (70 char) Charles H. Harper, M.D. Norfolk, NE. EIR issued 11/13/2020
FEI Number 3015685119
Firm Name Charles H. Harper, M.D.
Record Type EIR
State NE
Establishment Type Clinical InvestigatDrug Alerts and Statements
FDA Drug Alerts and StatementsCDER/Office of New Drugs Streamlined Nonclinical Studies and Acceptable New Approach Methodologies (NAMs)
It has become increasingly clear that new approach methodologies (NAMs)—when combined with knowledge of the pathway, results of pharmacology studies, and other relevant data—may offer ways to reduce animal testing.